Signaling inhibitors in metastatic renal cell carcinoma

Cancer Journal

Volumn 14, Issue 5, 2008, Pages 325-329

  Escudier, Bernard ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Renal cell carcinoma; Signaling inhibitors

Indexed keywords

ALPHA INTERFERON; AMG 386; AXITINIB; BEVACIZUMAB; CYTOKINE; EVEROLIMUS; HYBRID PROTEIN; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERFERON; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PAZOPANIB; PERIFOSINE; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VON HIPPEL LINDAU PROTEIN;

ANEMIA; ARTICLE; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG BINDING; DRUG EFFICACY; DRUG INHIBITION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TARGETING; FATIGUE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOPHOSPHATEMIA; KIDNEY CANCER; KIDNEY CARCINOMA; KIDNEY CELL; KIDNEY METASTASIS; LYMPHOCYTOPENIA; MONOTHERAPY; MUCOSA INFLAMMATION; NONHUMAN; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; RASH; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN MANIFESTATION; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL;

EID: 55349132393     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e3181867605     Document Type: Article

References (31)

1. Ohh M, Park CW, Ivan M, et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol. 2000;2:423-427.
2. Lamuraglia M, Escudier B, Chami L, et al. To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound. Eur J Cancer. 2006;42:2472-2479.
3. Rixe O, Meric J, Bloch J, et al. Surrogate markers of activity of AG-013736, a multi-target tyrosine kinase receptor inhibitor, in metastatic renal cell cancer (RCC). J Clin Oncol. 2005;23(380s):abstract 3003.
4. Sabers CJ, Martin MM, Brunn GJ, et al. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem. 1995;270:815-822.
5. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer. 2004;4:335-348.
6. DelBufalo D, Ciuffreda L, Trisciuoglio D, et al. Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res. 2006;66:5549-5554.
7. Thomas GV, Tran C, Mellinghoff IK, et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med. 2006;12:122-127.
8. Gnarra JR, Tory K, Weng Y, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet. 1994;7:85-90.
9. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427-434.
10. Bukowski RM, Kabbinavar FF, Figlin RA, et al. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 2007;25: 4536-4541.
11. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370:2103-2111.
12. Rini B, Halabi S, Rosenberg J, et al. CALGB 90206: a phase III trial of bevacizumab plus interferon-alpha monotherapy in metastatic renal cell carcinoma [abstract 350], Presented at the ASCO Genitourinary Cancers Symposium; February 14-16, 2008; San Francisco, CA.
13. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:16-24.
14. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006;295:2516-2524.
15. Motzer R, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-124.
16. Figlin R, Hutson TE, Tomczak P, et al. Overall survival with sunitinib versus interferon-alfa (IFN-α) as first-line treatment of metastatic renal cell carcinoma (mRCC). Proc ASCO. 2008, abstract 5024.
17. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:2505-2512.
18. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125-134.
19. Bukowski RM, Eisen T, Szcylick C, et al. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis. J Clin Oncol. 2007;25(18s):abstract 5023.
20. Szczylik, C, Demkoff T, Staehler M, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results. J Clin Oncol. 2007;25( 18s): abstract 5025.
21. Rixe O, Bukowski RM, Michaelson MD, et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol. 2007;8:975-984.
22. Rini BI, Wilding GT, Hudes G, et al. Axitinib (AG-013736; AG) in patients (pts) with metastatic renal cell cancer (RCC) refractory to sorafenib. J Clin Oncol. 2007;25(18s):abstract 5032.
23. Hutson TE, Davis ID, Machiels JP, et al. Pazopanib (GW786034) is active in metastatic renal cell carcinoma: interim results of a phase II randomized discontinuation trial. J Clin Oncol. 2007;25(18s):abstract 5031.
24. Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004;22:909-918.
25. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, Interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356: 2271-2281.
26. Jac J, Giessinger S, Khan M, et al. A phase II trial of RAD001 in patients (pts) with metastatic renal cell carcinoma (MRCC). J Clin Oncol. 2007;25(18s):abstract 5107.
27. Motzer RJ, Escudier B, Oudard S, et al. Everolimus for advanced renal cell carcinoma. Lancet. 2008 [Epub ahead of print].
28. Oliner J, Min H, Leal J, et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 2004;6: 507-516.
29. Stephenson J, Schreeder M, Waples J, et al. Perifosine (P), active as a single agent for renal cell carcinoma (RCC), now in phase I trials combined with tyrosine kinase inhibitors (TKJ). J Clin Oncol. 2007; 25(18s):abstract 15622.
30. Rini BI, George DI, Michaelson MD, et al. Efficacy and safety of sunitinib malate in bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol. 2006;24(18s):abstract 4522.
31. Choueri T, Plantade A, Elson P, et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol. 2008;26:127-131.